You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2/NEU negative

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Dapagliflozin 10mg
  • New Haven, Connecticut
    Yale Cancer Center Smilow Cancer Hospital
Aug 3, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Surgery for harvesting tumor-draining lymph nodes
  • +8 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023

Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

Enrolling by invitation
  • Germline BRCA-mutated HER2-negative Breast Cancer
  • Beijing, Beijing, China
    Breast Cancer, Peking University People's Hospital
Nov 14, 2022

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Sentinel Lymph Node Biopsy (SLNB)
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Trastuzumab Deruxtecan
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer Trial in Tianjin (fluzoparib+chidamide, fluzoparib+camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma
  • HRD+Breast Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 27, 2022

HER2-negative Breast Cancer Trial in Budapest (device, drug, procedure)

Recruiting
  • HER2-negative Breast Cancer
  • Oncotherm EHY-2030
  • +4 more
  • Budapest, Hungary
    Division of Oncology, Department of Internal Medicine and Oncolo
May 25, 2023

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 22, 2023

Luminal B/HER2-negative Breast Cancer Trial in Hangzhou (Dalpiciclib combined with aromatase inhibitors,

Recruiting
  • Luminal B/HER2-negative Breast Cancer
  • Dalpiciclib combined with aromatase inhibitors
  • anthracycline-cyclophosphamide followed by taxane
  • Hangzhou, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 30, 2022

HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal

Active, not recruiting
  • HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
  • +2 more
  • Ulm, Baden-Württemberg, Germany
    University Hospital Ulm -Department of Gynecology
Jul 27, 2022

Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine Trial in Changsha (UTD1 combined with capecitabine)

Recruiting
  • Metastatic HER2 Negative Breast Carcinoma
  • +3 more
  • UTD1 combined with capecitabine
  • Changsha, China
    Quchang Ouyang
Sep 9, 2022

Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)

Not yet recruiting
  • Gastroesophageal Adenocarcinoma
  • toripalimab FOLFOX
  • (no location specified)
Aug 3, 2023

Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

Completed
  • Breast Neoplasms
  • Shanghai, Shanghai, China
    Ruijin Hospital
Oct 26, 2022

Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

Not yet recruiting
  • Breast Cancer
  • +3 more
  • (no location specified)
Aug 4, 2023

Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma Trial in Woodville South (IMU-131, Irinotecan or Paclitaxel,

Not yet recruiting
  • Gastric Cancer
  • +5 more
  • IMU-131
  • +2 more
  • Woodville South, South Australia, Australia
    The Queen Elizabeth Hospital
Apr 12, 2022

Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)

Terminated
Has Results
  • Breast Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 31, 2022

Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,

Active, not recruiting
Has Results
  • Inflammatory Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Boston, Massachusetts
  • +1 more
Nov 28, 2022

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023